Pancreatic Cancer Research

ResearcherResearch Institute Hospital 12 de OctubreActive in the last 2 years

Rocio García‐Carbonero

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3342-397X; OpenAlex author ID A5048223620. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 10

  1. Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial. Co-author DOI 10.1038/s41591-026-04705-y↗
  2. A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial. Co-author DOI 10.1158/1078-0432.ccr-23-4026↗
  3. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  4. Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer. Co-author DOI 10.1056/evidoa2300144↗
  5. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA. Co-author DOI 10.1186/s13073-023-01171-w↗
  6. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … Co-author DOI 10.1016/j.annonc.2021.01.070↗
  7. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Last author DOI 10.1136/jitc-2020-002068↗
  8. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. First author DOI 10.1136/jitc-2021-003254↗
  9. TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. First author DOI 10.1007/s00280-019-03807-4↗
  10. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. First author DOI 10.1038/s41416-018-0246-z↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 8 shared papers, 2018–2026 · strength 1.04
  2. Roberto Pazo-Cid · 5 shared papers, 2023–2026 · strength 0.89
  3. Manuel M. Hidalgo · 5 shared papers, 2021–2026 · strength 0.81
  4. Carmen Guillén‐Ponce · 4 shared papers, 2023–2026 · strength 0.72
  5. Jaime Feliú · 3 shared papers, 2023–2025 · strength 0.50
  6. Bruno Bockorny · 2 shared papers, 2025 · strength 0.35
  7. Francesca Sarno · 2 shared papers, 2023–2025 · strength 0.34
  8. Jean‐Baptiste Bachet · 2 shared papers, 2021–2025 · strength 0.27
  9. Eric Van Cutsem · 2 shared papers, 2021–2025 · strength 0.27
  10. Karim Adnane Benhadji · 3 shared papers, 2018–2021 · strength 0.24
  11. Josep M. Tabernero · 3 shared papers, 2018–2021 · strength 0.24
  12. Davide Melisi · 3 shared papers, 2018–2021 · strength 0.24
  13. Mireya Cazorla · 1 shared paper, 2026 · strength 0.21
  14. Andrés Muñoz · 1 shared paper, 2026 · strength 0.21
  15. Vivek Sharma · 1 shared paper, 2026 · strength 0.21
  16. Luis Alfonso Rojas · 1 shared paper, 2026 · strength 0.21
  17. Edward Jae-Hoon Kim · 1 shared paper, 2026 · strength 0.21
  18. Chris Nevala-Plagemann · 1 shared paper, 2026 · strength 0.21
  19. Eva Martínez de Castro · 1 shared paper, 2026 · strength 0.21
  20. Do‐Youn Oh · 2 shared papers, 2021 · strength 0.21
  21. Carmen E. Guerra · 1 shared paper, 2025 · strength 0.19
  22. Senthil K. Muthuswamy · 1 shared paper, 2025 · strength 0.19
  23. Fernando Rivera Herrero · 1 shared paper, 2024 · strength 0.17
  24. Carles Pericay Pijaume · 1 shared paper, 2024 · strength 0.17
  25. Alfredo Carrato Mena · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.